Elapegademase-lvlr (Revcovi)

Revcovi (elapegademase‑lvlr) is covered only for the FDA‑approved treatment of ADA‑SCID in pediatric and adult patients and is not covered for non‑FDA‑approved/off‑label indications; coverage requires confirmation by bi‑allelic ADA gene mutations or absent/very low (<1%) ADA catalytic activity. Therapy must be prescribed by or in consultation with an immunologist/hematologist/oncologist or ADA‑SCID specialist, is given intramuscularly, approved for 12 months, and requires documentation of genetic/enzyme testing plus dosing documentation (Adagen‑naïve start 0.4 mg/kg/week divided into two doses; for Adagen transitions use the conversion Revcovi mg/kg = Adagen U/kg ÷ 150, or 0.2 mg/kg/week if Adagen dose unknown or ≤30 U/kg).

"For Adagen-naïve patients: documentation of ideal body weight to support dosing (starting dose 0."

Sign up to see full coverage criteria, indications, and limitations.